PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28488168-4	2018	We investigated TILs and PD-L1 status in TNBCs before or after preoperative systemic therapy (PST) to elucidate the clinical significance of PD-L1 expression.	tnbcs	41-46	CD274 molecule	Homo sapiens	25-30
30350349-5	2019	Concurrent TP53 mutations and NFIB overexpression (z-scores > 0) were observed in 77.9% of TNBCs, in contrast to 28.5% in non-TNBCs.	tnbcs	94-99	tumor protein p53	Homo sapiens	11-15
30350349-5	2019	Concurrent TP53 mutations and NFIB overexpression (z-scores > 0) were observed in 77.9% of TNBCs, in contrast to 28.5% in non-TNBCs.	tnbcs	94-99	nuclear factor I B	Homo sapiens	30-34
29805641-10	2018	These results indicate that EGF-conjugated NHS-PEG10000-DSPE phospholipid NPs loaded with curcumin may be useful for treating TNBCs that overexpress the EGF receptor.	tnbcs	126-131	epidermal growth factor	Homo sapiens	28-31
29805641-10	2018	These results indicate that EGF-conjugated NHS-PEG10000-DSPE phospholipid NPs loaded with curcumin may be useful for treating TNBCs that overexpress the EGF receptor.	tnbcs	126-131	epidermal growth factor receptor	Homo sapiens	153-165
29350614-2	2018	In this study, we show endothelial lipase (LIPG) is aberrantly overexpressed in basal-like TNBCs.	tnbcs	91-96	lipase G, endothelial type	Homo sapiens	23-41
29350614-2	2018	In this study, we show endothelial lipase (LIPG) is aberrantly overexpressed in basal-like TNBCs.	tnbcs	91-96	lipase G, endothelial type	Homo sapiens	43-47
32919338-10	2020	FRA showed positivity in 43% (129/300) of TNBCs in our study.	tnbcs	42-47	folate receptor alpha	Homo sapiens	0-3
29636136-7	2018	The implications of the results are then discussed for the specific targeting of TNBCs with LHRH-conjugated PEG-coated magnetite nanoparticles for the early detection and treatment of TNBC.	tnbcs	81-86	gonadotropin releasing hormone 1	Homo sapiens	92-96
29605826-14	2018	Furthermore, silencing of SphK1 by Ad-SPHK1-siRNA or SphK1 inhibitor PF543 sensitized TNBCs to 5-FU and doxorubicin.	tnbcs	86-91	sphingosine kinase 1	Homo sapiens	26-31
29605826-14	2018	Furthermore, silencing of SphK1 by Ad-SPHK1-siRNA or SphK1 inhibitor PF543 sensitized TNBCs to 5-FU and doxorubicin.	tnbcs	86-91	sphingosine kinase 1	Homo sapiens	38-43
29605826-14	2018	Furthermore, silencing of SphK1 by Ad-SPHK1-siRNA or SphK1 inhibitor PF543 sensitized TNBCs to 5-FU and doxorubicin.	tnbcs	86-91	sphingosine kinase 1	Homo sapiens	53-58
28053523-4	2017	In this study, the anti-MUC1 aptamer was used as a drug delivery system (DDS) for a radioactive polymeric nanoparticle (NP) in the imaging of TNBCs.	tnbcs	142-147	mucin 1, cell surface associated	Homo sapiens	24-28
29281678-5	2017	We have previously shown that TNBCs are active for oncogenic Wnt10b/beta-catenin signaling and that WNT10B ligand and its downstream target HMGA2 are predictive of poorer outcomes and are strongly associated with chemoresistant TNBC metastatic disease.	tnbcs	30-35	Wnt family member 10B	Homo sapiens	61-67
29281678-5	2017	We have previously shown that TNBCs are active for oncogenic Wnt10b/beta-catenin signaling and that WNT10B ligand and its downstream target HMGA2 are predictive of poorer outcomes and are strongly associated with chemoresistant TNBC metastatic disease.	tnbcs	30-35	catenin beta 1	Homo sapiens	68-80
29261144-4	2017	Recently, the protein phosphatase 2A (PP2A) has been found to regulate the phosphorylation of some substrates involved in the relevant target of TNBC, such as cell cycle control, DNA damage responses, epidermal growth factor receptor, immune modulation and cell death resistance, which may be the effective therapeutic strategies or influence drug sensitivity to TNBCs.	tnbcs	363-368	protein phosphatase 2 phosphatase activator	Homo sapiens	38-42
29261144-5	2017	Furthermore, PP2A has also been found that could induce ER re-expression in ER-negative breast cancer cells, and which suggests PP2A could promote the sensitivity of tamoxifen to TNBCs as a resistance reversal agent.	tnbcs	179-184	protein phosphatase 2 phosphatase activator	Homo sapiens	13-17
29261144-5	2017	Furthermore, PP2A has also been found that could induce ER re-expression in ER-negative breast cancer cells, and which suggests PP2A could promote the sensitivity of tamoxifen to TNBCs as a resistance reversal agent.	tnbcs	179-184	estrogen receptor 1	Homo sapiens	56-58
29261144-5	2017	Furthermore, PP2A has also been found that could induce ER re-expression in ER-negative breast cancer cells, and which suggests PP2A could promote the sensitivity of tamoxifen to TNBCs as a resistance reversal agent.	tnbcs	179-184	estrogen receptor 1	Homo sapiens	76-78
29261144-5	2017	Furthermore, PP2A has also been found that could induce ER re-expression in ER-negative breast cancer cells, and which suggests PP2A could promote the sensitivity of tamoxifen to TNBCs as a resistance reversal agent.	tnbcs	179-184	protein phosphatase 2 phosphatase activator	Homo sapiens	128-132
29416635-8	2018	In assessments of recurrence/metastasis-free survival probability, high-levels of OTUD7B transcripts strongly predicted a poor prognosis and unfavorable response to paclitaxel-based chemotherapy in patients with TNBCs.	tnbcs	212-217	OTU deubiquitinase 7B	Homo sapiens	82-88
26170011-5	2015	Expressions of vimentin, CD44(+)/CD24(-), and CD146 were more frequent in basal-like TNBCs than non-basal-like TNBCs.	tnbcs	85-90	vimentin	Homo sapiens	15-23
27747192-5	2016	Upregulation of choline kinase-alpha, an enzyme of the Kennedy pathway that phosphorylates free choline (Cho) to phosphocholine (PCho), is a major contributor to the increased PCho content detected in TNBCs.	tnbcs	201-206	choline kinase alpha	Homo sapiens	16-36
27184484-7	2016	The rate of focal positivity or positivity for GATA3 was significantly higher in the molecular apocrine type (73.9%, 17/23) than in other types of TNBCs (P=.001).	tnbcs	147-152	GATA binding protein 3	Homo sapiens	47-52
27058032-5	2016	Despite lower pathologic complete response (pCR) rates with neoadjuvant therapy, patients with AR-dependent TNBCs have a better prognosis than those with TNBCs that are not AR-dependent.	tnbcs	108-113	androgen receptor	Homo sapiens	95-97
26170011-5	2015	Expressions of vimentin, CD44(+)/CD24(-), and CD146 were more frequent in basal-like TNBCs than non-basal-like TNBCs.	tnbcs	85-90	CD44 molecule (Indian blood group)	Homo sapiens	25-29
26170011-5	2015	Expressions of vimentin, CD44(+)/CD24(-), and CD146 were more frequent in basal-like TNBCs than non-basal-like TNBCs.	tnbcs	85-90	CD24 molecule	Homo sapiens	33-37
26170011-5	2015	Expressions of vimentin, CD44(+)/CD24(-), and CD146 were more frequent in basal-like TNBCs than non-basal-like TNBCs.	tnbcs	85-90	melanoma cell adhesion molecule	Homo sapiens	46-51
25588857-10	2015	CONCLUSIONS: The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.	tnbcs	139-144	androgen receptor	Homo sapiens	64-66
25698149-3	2015	In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes.	tnbcs	82-87	tumor protein p53	Homo sapiens	50-53
25588857-10	2015	CONCLUSIONS: The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.	tnbcs	139-144	androgen receptor	Homo sapiens	119-121
25588857-10	2015	CONCLUSIONS: The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.	tnbcs	139-144	androgen receptor	Homo sapiens	119-121
25145503-3	2015	RESULTS: AR expression was found in 17.7% (87/492) of TNBCs.	tnbcs	54-59	androgen receptor	Homo sapiens	9-11
25395319-7	2014	TNBCs with a high CD8+/FOXP3+ ratio and high Ki-67 had the highest pCR rate (70%) following NAC.	tnbcs	0-5	CD8a molecule	Homo sapiens	18-21
25395319-7	2014	TNBCs with a high CD8+/FOXP3+ ratio and high Ki-67 had the highest pCR rate (70%) following NAC.	tnbcs	0-5	forkhead box P3	Homo sapiens	23-28
25395319-10	2014	TNBCs with a high CD8+/FOXP3+ ratio were more sensitive to anthracycline and taxane-based chemotherapeutic regimens, and the CD8+/FOXP3+ ratio in conjunction with Ki-67 could predict pCR following NAC in TNBC.	tnbcs	0-5	CD8a molecule	Homo sapiens	18-21
25395319-10	2014	TNBCs with a high CD8+/FOXP3+ ratio were more sensitive to anthracycline and taxane-based chemotherapeutic regimens, and the CD8+/FOXP3+ ratio in conjunction with Ki-67 could predict pCR following NAC in TNBC.	tnbcs	0-5	forkhead box P3	Homo sapiens	23-28
25395319-10	2014	TNBCs with a high CD8+/FOXP3+ ratio were more sensitive to anthracycline and taxane-based chemotherapeutic regimens, and the CD8+/FOXP3+ ratio in conjunction with Ki-67 could predict pCR following NAC in TNBC.	tnbcs	0-5	CD8a molecule	Homo sapiens	125-128
25395319-10	2014	TNBCs with a high CD8+/FOXP3+ ratio were more sensitive to anthracycline and taxane-based chemotherapeutic regimens, and the CD8+/FOXP3+ ratio in conjunction with Ki-67 could predict pCR following NAC in TNBC.	tnbcs	0-5	forkhead box P3	Homo sapiens	130-135
24999743-8	2014	The 127 older patients with TNBCs showed lower rates of Ki67 and CK 7/8 positivity and high rates of bcl2 and CK18 positivity when compared with their younger counterparts (p<0.05).	tnbcs	28-33	BCL2 apoptosis regulator	Homo sapiens	101-105
25153718-5	2014	Moreover, SPHK1 inhibition by siRNA knockdown or treatment with SKI-5C sensitizes TNBCs to chemotherapeutic drugs.	tnbcs	82-87	sphingosine kinase 1	Mus musculus	10-15
24999743-8	2014	The 127 older patients with TNBCs showed lower rates of Ki67 and CK 7/8 positivity and high rates of bcl2 and CK18 positivity when compared with their younger counterparts (p<0.05).	tnbcs	28-33	keratin 18	Homo sapiens	110-114
24670641-9	2014	Hypoxia-inducing factor 1alpha (HIF1alpha) is known to be hyperactivated in TNBCs.	tnbcs	76-81	hypoxia inducible factor 1 subunit alpha	Homo sapiens	32-41
24138071-6	2014	RESULTS: Our study revealed AKT-3 amplification and deletions in 11% (9/82) and 13% (11/82) of TNBCs, respectively.	tnbcs	95-100	AKT serine/threonine kinase 3	Homo sapiens	28-33
24764583-11	2014	PD-L1 is expressed in 20% of TNBCs, suggesting PD-L1 as a therapeutic target in TNBCs.	tnbcs	29-34	CD274 molecule	Homo sapiens	0-5
24764583-11	2014	PD-L1 is expressed in 20% of TNBCs, suggesting PD-L1 as a therapeutic target in TNBCs.	tnbcs	29-34	CD274 molecule	Homo sapiens	47-52
24764583-11	2014	PD-L1 is expressed in 20% of TNBCs, suggesting PD-L1 as a therapeutic target in TNBCs.	tnbcs	80-85	CD274 molecule	Homo sapiens	0-5
24764583-11	2014	PD-L1 is expressed in 20% of TNBCs, suggesting PD-L1 as a therapeutic target in TNBCs.	tnbcs	80-85	CD274 molecule	Homo sapiens	47-52
24385208-7	2014	RESULTS: FGFR1, FGFR2, and FGF2 expression were found in 16.2 % (24 of 148), 12.8 % (19 of 148), and 12.8 % (19 of 148) of TNBCs, respectively.	tnbcs	123-128	fibroblast growth factor receptor 1	Homo sapiens	9-14
24385208-7	2014	RESULTS: FGFR1, FGFR2, and FGF2 expression were found in 16.2 % (24 of 148), 12.8 % (19 of 148), and 12.8 % (19 of 148) of TNBCs, respectively.	tnbcs	123-128	fibroblast growth factor receptor 2	Homo sapiens	16-21
24104963-6	2013	Immunohistochemical analysis revealed low, moderate and high DPD expression in 64%, 29% and 7% of all TNBCs, and in 40%, 53% and 7% of TNBCs with DPYD CNVs, respectively.	tnbcs	102-107	dihydropyrimidine dehydrogenase	Homo sapiens	61-64
24385208-7	2014	RESULTS: FGFR1, FGFR2, and FGF2 expression were found in 16.2 % (24 of 148), 12.8 % (19 of 148), and 12.8 % (19 of 148) of TNBCs, respectively.	tnbcs	123-128	fibroblast growth factor 2	Homo sapiens	27-31
24421076-3	2014	Breaching of the BBB in vivo by TNBCs resulted in increased BBB permeability and changes in ZO-1 and claudin-5 tight junction (TJ) protein structures.	tnbcs	32-37	tight junction protein 1	Mus musculus	92-96
24421076-3	2014	Breaching of the BBB in vivo by TNBCs resulted in increased BBB permeability and changes in ZO-1 and claudin-5 tight junction (TJ) protein structures.	tnbcs	32-37	claudin 5	Mus musculus	101-110
23246963-14	2014	Our results show that TNBCs are particularly sensitive to inhibition of the mTOR pathway, and indicate that mTOR targeting may be a more efficient anti-TNBC therapy than exclusively acting on the mTORC1 branch of the pathway.	tnbcs	22-27	mechanistic target of rapamycin kinase	Homo sapiens	76-80
23246963-14	2014	Our results show that TNBCs are particularly sensitive to inhibition of the mTOR pathway, and indicate that mTOR targeting may be a more efficient anti-TNBC therapy than exclusively acting on the mTORC1 branch of the pathway.	tnbcs	22-27	mechanistic target of rapamycin kinase	Homo sapiens	108-112
24016618-4	2013	We hypothesized that pretreatment with mifepristone, a GR antagonist, would potentiate the efficacy of chemotherapy in GR+ TNBCs by inhibiting the antiapoptotic signaling pathways of GR and increasing the cytotoxic efficiency of chemotherapy.	tnbcs	123-128	nuclear receptor subfamily 3, group C, member 1	Mus musculus	55-57
24016618-4	2013	We hypothesized that pretreatment with mifepristone, a GR antagonist, would potentiate the efficacy of chemotherapy in GR+ TNBCs by inhibiting the antiapoptotic signaling pathways of GR and increasing the cytotoxic efficiency of chemotherapy.	tnbcs	123-128	nuclear receptor subfamily 3, group C, member 1	Mus musculus	119-121
24016618-4	2013	We hypothesized that pretreatment with mifepristone, a GR antagonist, would potentiate the efficacy of chemotherapy in GR+ TNBCs by inhibiting the antiapoptotic signaling pathways of GR and increasing the cytotoxic efficiency of chemotherapy.	tnbcs	123-128	nuclear receptor subfamily 3, group C, member 1	Mus musculus	119-121
23696021-9	2013	And 34.3 % TNBCs showed moderate to strong positive SNCG expression.	tnbcs	11-16	synuclein gamma	Homo sapiens	52-56
23979844-2	2013	TNBCs are associated with an overall poor prognosis because they lack expression of therapeutic targets like ERalpha and are biologically more aggressive.	tnbcs	0-5	estrogen receptor 1	Homo sapiens	109-116
23633491-6	2013	Together these findings offer a rationale for dual inhibition of IL-6/IL-8 signaling as a therapeutic strategy to improve outcomes for patients with TNBCs.	tnbcs	149-154	interleukin 6	Homo sapiens	65-69
23633491-6	2013	Together these findings offer a rationale for dual inhibition of IL-6/IL-8 signaling as a therapeutic strategy to improve outcomes for patients with TNBCs.	tnbcs	149-154	C-X-C motif chemokine ligand 8	Homo sapiens	70-74
23445611-10	2013	Taken together, our findings suggest that FZD8-mediated Wnt signaling may play a major role in mediating resistance to chemotherapy, making it a potential target to enhance chemotherapeutic efficacy in patients with TNBCs.	tnbcs	216-221	frizzled class receptor 8	Homo sapiens	42-46
23046633-9	2012	Overexpression of EGFR was significantly associated with pCR rate in patients with TNBCs (P < 0.001).	tnbcs	83-88	epidermal growth factor receptor	Homo sapiens	18-22
22952619-3	2012	We have identified the WAVE3 protein, which is a critical regulator of actin cytoskeleton dynamics that are required for the motility and invasion of cancer cells through its activation of the Arp2/3 complex, as a key regulator of the different steps of the invasion-metastasis cascade in BC, especially in the more aggressive TNBCs.	tnbcs	327-332	WASP family member 3	Homo sapiens	23-28
22952619-3	2012	We have identified the WAVE3 protein, which is a critical regulator of actin cytoskeleton dynamics that are required for the motility and invasion of cancer cells through its activation of the Arp2/3 complex, as a key regulator of the different steps of the invasion-metastasis cascade in BC, especially in the more aggressive TNBCs.	tnbcs	327-332	actin related protein 2	Homo sapiens	193-197
22674792-13	2012	Taking this further, we report that P-RSK(S221/227) is present in primary TNBCs and correlates with P-YB-1(S102) as well as CD44.	tnbcs	74-79	ribosomal protein S6 kinase A3	Homo sapiens	38-41
22674792-13	2012	Taking this further, we report that P-RSK(S221/227) is present in primary TNBCs and correlates with P-YB-1(S102) as well as CD44.	tnbcs	74-79	Y-box binding protein 1	Homo sapiens	102-106
22674792-13	2012	Taking this further, we report that P-RSK(S221/227) is present in primary TNBCs and correlates with P-YB-1(S102) as well as CD44.	tnbcs	74-79	CD44 molecule (Indian blood group)	Homo sapiens	124-128
22472120-5	2012	We provide evidence that by regulating cellular SM levels, CERT determines the signaling output of the EGF receptor (EGFR/ErbB1), which is upregulated in approximately 70% of TNBCs.	tnbcs	175-180	ceramide transporter 1	Homo sapiens	59-63
22472120-5	2012	We provide evidence that by regulating cellular SM levels, CERT determines the signaling output of the EGF receptor (EGFR/ErbB1), which is upregulated in approximately 70% of TNBCs.	tnbcs	175-180	epidermal growth factor receptor	Homo sapiens	117-121
22472120-5	2012	We provide evidence that by regulating cellular SM levels, CERT determines the signaling output of the EGF receptor (EGFR/ErbB1), which is upregulated in approximately 70% of TNBCs.	tnbcs	175-180	epidermal growth factor receptor	Homo sapiens	122-127
22893791-4	2012	Six of the 26 genes tested (VEGFA, SRC, PARP1, PTK2, RAF1, and FGFR3) were significantly upregulated in 13% to 46% of the TNBCs.	tnbcs	122-127	vascular endothelial growth factor A	Homo sapiens	28-33
22893791-4	2012	Six of the 26 genes tested (VEGFA, SRC, PARP1, PTK2, RAF1, and FGFR3) were significantly upregulated in 13% to 46% of the TNBCs.	tnbcs	122-127	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	35-38
22893791-4	2012	Six of the 26 genes tested (VEGFA, SRC, PARP1, PTK2, RAF1, and FGFR3) were significantly upregulated in 13% to 46% of the TNBCs.	tnbcs	122-127	poly(ADP-ribose) polymerase 1	Homo sapiens	40-45
22893791-4	2012	Six of the 26 genes tested (VEGFA, SRC, PARP1, PTK2, RAF1, and FGFR3) were significantly upregulated in 13% to 46% of the TNBCs.	tnbcs	122-127	protein tyrosine kinase 2	Homo sapiens	47-51
22893791-4	2012	Six of the 26 genes tested (VEGFA, SRC, PARP1, PTK2, RAF1, and FGFR3) were significantly upregulated in 13% to 46% of the TNBCs.	tnbcs	122-127	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	53-57
22893791-4	2012	Six of the 26 genes tested (VEGFA, SRC, PARP1, PTK2, RAF1, and FGFR3) were significantly upregulated in 13% to 46% of the TNBCs.	tnbcs	122-127	fibroblast growth factor receptor 3	Homo sapiens	63-68